+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Precision Medicine Market: Focus on Precision Medicine Ecosystem, Applications, 13 Countries Mapping, and Competitive Landscape - Analysis and Forecast: 2018-2028

  • ID: 4748231
  • Report
  • Region: Global
  • 544 pages
  • BIS Research
1 of 7
Global Precision Medicine Market to Reach $216.75 Billion by 2028

FEATURED COMPANIES

  • Abbott Laboratories
  • Astra Zeneca PLC
  • Epic Sciences, Inc.
  • IBM Corporation
  • MDxHealth, Inc.
  • Partek, Inc.
  • MORE

Various advancements in the life sciences industry have paved the way for development of several precision medicine solutions. It is one of the most modernized trends in the healthcare industry that has projected tremendous level of progress in the last few years. The completion of the Human Genome project in 2003 and the precision medicine initiative in 2015 provided a path of opportunity to introduce new scientific, medical, and business models in the precision medicine market. The sole idea behind the development of precision medicine solution is to provide targeted therapies to population based on their genomic structure. Therefore, the application of ‘omics’ (genomics, proteomics, transcriptomics) analysis is widely used in this market. The precision medicine market is a multibillion market which consists of innumerable companies involved in the research and development, manufacturing and commercialization of several novel drugs and diagnostic kits to boost the Precision Medicine workflow.

Currently, the precision medicine market is gaining preference among the masses due to the growth of personal healthcare devices and integration of smart technologies in the healthcare system. In addition, increasing collaborations and partnerships between various ecosystem players are aiding in the robust growth of the precision medicine market. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment, technological innovation and advancement (including Biomarker-based tests/kits, next gene sequencing, and precise imaging), government support and regulations, which consequently, have created a demand for the precision medicine solutions. Governmental regulations and standards are sustaining the growth and development of the precision medicine market. The primary aim of these regulations is to make precision medicines more adaptable and focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases, among others.

The purpose of this study is to gain a holistic view of the precision medicine market in terms of various influencing factors, such as recent trends, technological advancements, and role of various key stakeholders in the market. The report constitutes an in-depth study of the global precision medicine market, including a thorough analysis of the products across different regions. The study also presents a detailed analysis of the market trends, and the market size for the period 2017-2028, wherein 2017 is the base year, and the years from 2018 to 2028 constitute the forecast period. The report covers all the prevalent trends which are expected to play a significant role in the growth of the market over the forecast period. It also highlights various drivers, restraints, challenges, and opportunities which are expected to influence the market's growth during the forecast period. The report is focused on the global precision medicine market; ecosystem and technology, application, their market dynamics, growth prospect mapping, SWOT analysis, Porter’s Five Forces, market share analysis, pipeline analysis, and country-wise analysis.

The study provides a holistic perspective on the market growth, in terms of revenue estimates, across different geographies which include North America, Europe, Asia-Pacific (APAC), Latin America, and Rest of the World (RoW). The report provides cross-sectional analysis of the global precision medicine market in terms of market estimates, and projections, for all the segments across different geographical regions. The regions have been further segmented to cover the in-depth country level analysis. The North American region has been segmented into the U.S., and Canada. Similarly, Europe has been further segmented into the U.K., Germany, France, Spain, Italy, and Rest of Europe. Asia Pacific has been segmented into China, Japan, Australia, India, and Rest of Asia Pacific. Latin America has been segmented into Brazil, Mexico, and Rest of Latin America. Moreover, Rest of the World (RoW) has been further segmented into Middle East and Africa.

Key questions answered in the report:

  • What are the major market drivers, challenges, and opportunities in the global precision medicine market?
  • What are the underlying structures resulting in the emerging trends within the precision medicine market?
  • What was the market value of the leading segments and sub-segments of the global precision medicine market in 2017?
  • How will each segment of the global precision medicine market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period 2018- 2028?
  • What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?
  • What are the key ecosystem type in the global precision medicine market? What are the major benefits of each type?
  • How has the market been segmented on the basis of application type? Which application type is dominating the global precision medicine market and what is the reason behind such domination?
  • Which ecosystem type is having the most promising growth and in which application type?
  • What is the market share of each of the companies in the global precision medicine market and what are their contributions?
  • What is the scope of each type of ecosystem in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
  • What is the growth potential of precision medicine in each region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?
  • How many countries are covered in each geographical region? Which country is currently dominating the precision medicine market?

The key players which have been contributing significantly to the precision medicine market include Abbott Laboratories, Almac Group, Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, ASURAGEN, INC., bioMerieux SA, BRISTOL-MYERS SQUIBB COMPANY, CETICS Healthcare Technologies GmbH, Eli-Lilly and Company,  F. Hoffmann-La Roche AG, GE Healthcare, GlaxoSmithKline, IBM Corporation, Illumina, Inc., Intomics A/S, JOHNSON & JOHNSON, Laboratory Corporation of America, Merck KGaA, Novartis AG, Pfizer, Inc., QIAGEN, Quest Diagnostics, SANOFI, Teva Pharmaceuticals Limited, and Thermo Fisher Scientific, among others.

READ MORE
Note: Product cover images may vary from those shown
2 of 7

FEATURED COMPANIES

  • Abbott Laboratories
  • Astra Zeneca PLC
  • Epic Sciences, Inc.
  • IBM Corporation
  • MDxHealth, Inc.
  • Partek, Inc.
  • MORE

Executive Summary
1 Market Overview
1.1 Introduction
1.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine
1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
1.4 Initiatives and Programs
1.5 Assumptions and Limitations for Market Size Calculations
1.6 Precision Medicine: Enabling Technologies
1.6.1 Innovators
1.6.1.1 3D DNA Printing
1.6.1.1.1 Introduction
1.6.1.1.2 Role of 3D DNA Printing
1.6.1.2 RNA-Seq
1.6.1.2.1 Introduction
1.6.1.2.2 Role of RNA-Seq in Precision Medicine
1.6.1.2.3 Key Players
1.6.1.3 4D Molecular Imaging
1.6.1.3.1 Introduction
1.6.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
1.6.1.3.3 Key Players
1.6.2 Early Adopters
1.6.2.1 CRISPR
1.6.2.1.1 Introduction
1.6.2.1.2 Role of CRISPR in Precision Medicine
1.6.2.1.3 Key Players
1.6.2.2 Blockchain
1.6.2.2.1 Introduction
1.6.2.2.2 Role of Blockchain in Precision Medicine
1.6.2.2.3 Key Players
1.6.2.3 Imaging Informatics
1.6.2.3.1 Introduction
1.6.2.3.2 Role of Imaging Informatics in Precision Medicine
1.6.2.3.3 Key Players
1.6.3 Early Majority
1.6.3.1 Artificial Intelligence (AI)
1.6.3.1.1 Introduction
1.6.3.1.2 Role of Artificial Intelligence in Precision Medicine
1.6.3.1.3 Key Players
1.6.3.2 Circulating free DNA (cfDNA)
1.6.3.2.1 Introduction
1.6.3.2.2 Role of cfDNA in Precision Medicine
1.6.3.2.3 Key Players
1.6.3.3 Big Data
1.6.3.3.1 Introduction
1.6.3.3.2 Role of Big Data in Precision Medicine
1.6.3.3.3 Key Players
1.6.3.4 Next-Generation Sequencing (NGS)
1.6.3.4.1 Introduction
1.6.3.4.2 Role of NGS in Precision Medicine
1.6.3.4.3 Key Players
1.6.3.5 Health Informatics
1.6.3.5.1 Introduction
1.6.3.5.2 Role of Health informatics in Precision Medicine
1.6.3.5.3 Key players
1.6.3.6 Bioinformatics
1.6.3.6.1 Introduction
1.6.3.6.2 Role of Bioinformatics in Precision Medicine
1.6.3.6.3 Key Players
1.6.4 Late Majority
1.6.4.1 Polymerase Chain Reactions (PCR)
1.6.4.1.1 Introduction
1.6.4.1.2 Role of PCR in Precision Medicine
1.6.4.1.3 Key players
1.6.4.2 Microarray
1.6.4.2.1 Role of Microarray in Precision Medicine
1.6.4.2.2 Key Players

2 Market Dynamics
2.1 Impact Analysis
2.2 Market Drivers
2.2.1 Advancement of Sequencing Technologies
2.2.2 Rising Prevalence of Chronic Diseases
2.2.3 Growing Demand for Preventive Care
2.2.4 Shifting the Significance in Medicine, from Reaction to Prevention
2.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test
2.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe
2.3 Market Restraints
2.3.1 Unified Framework for Data Integration
2.3.2 Limited Knowledge About Precision Medicine Application
2.3.3 Lack of Robust Reimbursement Landscape
2.3.4 Regulatory Hurdles
2.4 Market Opportunities
2.4.1 Targeted Gene Therapy
2.4.2 Expansion into the Emerging Markets
2.4.3 Collaboration and Partnerships Across Value Chain Would Accelerate the Market Entry

3 Competitive Insights
3.1 Key Developments and Strategies
3.1.1 Joint Ventures, Partnerships, Agreements, and Collaborations
3.1.2 Product launches, Enhancements, and Upgradation
3.1.3 Product Approvals
3.1.4 Merger and Acquisitions
3.1.5 Business Expansion
3.1.6 Other Developments
3.2 Market Share Analysis
3.2.1 Market Share Analysis by Applied Sciences, 2017
3.2.2 Market Share Analysis by Precision Diagnostics, 2017
3.2.3 Market Share Analysis by Precision Therapeutics, 2017
3.2.4 Market Share Analysis by Digital Health and IT, 2017
3.3 Industry Attractiveness
3.3.1 Definition of Suppliers and Buyers in the Precision Medicine Market
3.3.2 Bargaining Power of Suppliers
3.3.3 Bargaining Power of Buyers
3.3.4 Threat of New Entrants
3.3.5 Threat of Substitute Products
3.3.6 Intensity of Competitive Rivalry
3.4 Supply Chain Analysis

4 Industry Insights
4.1 Patent Analysis
4.2 Legal Requirements and Regulations
4.3 Pipeline Analysis

5 Global Precision Medicine Market (by Ecosystem)
5.1 Overview
5.2 Applied Sciences
5.2.1 Genomics
5.2.1.1 Polymerase Chain Reaction (PCR)
5.2.1.2 Precision Medicine Next-Generation Sequencing (PM NGS)
5.2.1.3 Genome Editing
5.2.1.4 Other Technologies
5.2.2 Pharmacogenomics
5.2.3 Other Applied Sciences
5.3 Precision Diagnostics
5.3.1 Molecular Diagnostics (MDx)
5.3.1.1 Non-invasive Prenatal Testing (NIPT)
5.3.1.2 Companion Diagnostics
5.3.1.3 Liquid Biopsy
5.3.1.4 Other Molecular Diagnostics
5.3.2 Medical Imaging
5.3.2.1 Imaging Analytics
5.3.2.2 Imaging Computer-Aided Detection (CADx)
5.4 Digital Health and Information Technology
5.4.1 Clinical Decision Support Systems (CDSS)
5.4.2 Big Data Analytics
5.4.3 IT Infrastructure
5.4.4 Genomics Informatics
5.4.5 In-Silico Informatics
5.4.6 Mobile Health
5.5 Precision Therapeutics
5.5.1 Clinical Trials
5.5.2 Cell Therapy
5.5.3 Drug Discovery and Research
5.5.4 Gene Therapy

6 Global Precision Medicine Market (by Application)
6.1 Overview
6.2 Oncology
6.2.1 Government Initiatives
6.2.2 Key Insights
6.2.3 Drivers and Challenges
6.2.4 Cancer Precision Medicine Drugs and Indications
6.2.5 Recent Key Developments
6.3 Infectious Diseases
6.3.1 Infectious Diseases Precision Medicine Drugs and Indications
6.4 Neurology/Physiatry
6.4.1 Neurology Precision Medicine Drugs and Indications
6.5 Cardiovascular
6.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and Indications
6.6 Lifestyle and Endocrinology
6.6.1 Endocrinology Precision Medicine Drugs and Indications
6.7 Gastroenterology
6.7.1 Gastroenterology Precision Medicine Drugs and Indications
6.8 Other Applications
6.8.1 Precision Drugs for Other Applications

7 Global Precision Medicine Market (by Region)
7.1 Overview
7.2 North America
7.2.1 North America Precision Medicine Market Dynamics
7.2.2 The U.S.
7.2.2.1 Market Statistics
7.2.2.2 Overview of Precision Medicine
7.2.2.3 Key Trends
7.2.2.4 Promoting Factors
7.2.2.5 Recent Key Developments
7.2.2.6 Funding Scenario/Investments
7.2.2.7 Regulatory Scenario
7.2.2.8 Key Players
7.2.3 Canada
7.2.3.1 Market Statistics
7.2.3.2 Overview of Precision Medicine
7.2.3.3 Key Trends
7.2.3.4 Promoting Factors
7.2.3.5 Recent Key Developments
7.2.3.6 Funding Scenario
7.2.3.7 Regulatory Scenario
7.2.3.8 Key Players
7.3 Europe
7.3.1 Europe Precision Medicine Market Dynamics
7.3.2 Germany
7.3.2.1 Market Statistics
7.3.2.2 Overview of Precision Medicine
7.3.2.3 Key Trends
7.3.2.4 Promoting Factors
7.3.2.5 Recent Key Developments
7.3.2.5.1 Key Players
7.3.3 France
7.3.3.1 Market Statistics
7.3.3.2 Overview of Precision Medicine
7.3.3.3 Key Trends
7.3.3.4 Promoting Factors
7.3.3.5 Recent Key Developments
7.3.3.6 Key Players
7.3.4 Italy
7.3.4.1 Market Statistics
7.3.4.2 Overview of Precision Medicine
7.3.4.3 Key Trends
7.3.4.4 Promoting Factors
7.3.4.5 Recent Key Developments
7.3.4.6 Funding Scenario/Investments
7.3.5 The U.K.
7.3.5.1 Market Statistics
7.3.5.2 Overview of Precision Medicine
7.3.5.3 Key Trends
7.3.5.4 Promoting Factors
7.3.5.5 Recent Key Developments
7.3.5.6 Funding Scenario/Investments
7.3.5.7 Key Players
7.3.6 Spain
7.3.6.1 Market Statistics
7.3.6.2 Overview of Precision Medicine
7.3.6.3 Key Trends
7.3.6.4 Promoting Factors
7.3.6.5 Recent Key Developments
7.3.6.6 Key Players
7.3.7 Rest-of-Europe
7.3.7.1 Market Statistics
7.3.7.2 Switzerland
7.4 Asia-Pacific (APAC)
7.4.1 Asia-Pacific Precision Medicine Market Dynamics
7.4.1.1 China
7.4.1.2 Market Statistics
7.4.1.3 Overview of Precision Medicine
7.4.1.4 Key Trends
7.4.1.5 Promoting Factors
7.4.1.6 Recent Key Developments
7.4.1.7 Key Players
7.4.2 Japan
7.4.2.1 Market Statistics
7.4.2.2 Overview of Precision Medicine
7.4.2.3 Key Trends
7.4.2.4 Promoting Factors
7.4.2.5 Recent Key Developments
7.4.2.6 Reimbursement Scenario
7.4.2.7 Key Players
7.4.3 Australia
7.4.3.1 Market Statistics
7.4.3.2 Overview of Precision Medicine
7.4.3.3 Key Trends
7.4.3.4 Promoting Factors
7.4.3.5 Recent Key Developments
7.4.3.6 Regulatory Scenario
7.4.3.7 Key Players
7.4.4 India
7.4.4.1 Market Statistics
7.4.4.2 Overview of Precision Medicine
7.4.4.3 Key Trends
7.4.4.4 Promoting Factors
7.4.4.5 Recent Key Developments
7.4.4.6 Key Players
7.4.5 Rest-of-Asia-Pacific (RoAPAC)
7.4.5.1 Market Statistics
7.4.5.2 Singapore
7.4.5.2.1 Regulatory Framework
7.4.5.3 South Korea
7.4.5.4 Vietnam
7.5 Latin America
7.5.1 Latin America Precision Medicine Market Dynamics
7.5.2 Brazil
7.5.2.1 Market Statistics
7.5.2.2 Overview of Precision Medicine
7.5.3 Mexico
7.5.3.1 Market Statistics
7.5.3.2 Overview of Precision Medicine
7.5.3.3 Recent Key Developments
7.5.4 Rest-of-Latin America (RoLA)
7.5.4.1 Market Statistics
7.6 Rest-of-the-World (RoW)
7.6.1 Market Statistics
7.6.1.1 Middle East Precision Market Dynamics
7.6.1.2 Africa Precision Medicine Market Dynamics
7.6.1.3 Israel
7.6.1.4 Saudi Arabia
7.6.1.5 United Arab Emirates
7.6.1.6 South Africa
7.6.1.7 Russia

8 Company Profile
8.1 Abbott Laboratories.
8.1.1 Company Overview
8.1.2 Role of Abbott Laboratories, Inc.in the Global Precision Medicine Market
8.1.3 Key Insights about Financial Health of the Company
8.1.4 SWOT Analysis
8.2 Almac Group Ltd.
8.2.1 Company Overview
8.2.2 Role of Almac Group Ltd. in the Global Precision Medicine Market
8.2.3 SWOT Analysis
8.3 Amgen Inc.
8.3.1 Company Overview
8.3.2 Role of Amgen Inc. in the Global Precision Medicine Market
8.3.3 Key Insights about Financial Health of the Company
8.3.4 SWOT Analysis
8.4 ANGLE plc
8.4.1 Company Overview
8.4.2 Role of ANGLE plc in the Global Precision Medicine Market
8.4.3 Key Insights about Financial Health of the Company
8.4.4 SWOT Analysis
8.5 Astellas Pharma Inc.
8.5.1 Company Overview
8.5.2 Role of Astellas Pharma Inc.in the Global Precision Medicine Market
8.5.3 Key Insights about Financial Health of the Company
8.5.4 SWOT Analysis
8.6 Astra Zeneca PLC
8.6.1 Company Overview
8.6.2 Role of Astra Zeneca PLC in the Global Precision Medicine Market
8.6.3 Key Insights about Financial Health of the Company
8.6.4 SWOT Analysis
8.7 ASURAGEN INC.
8.7.1 Company Overview
8.7.2 Role of ASURAGEN Inc. in the Global Precision Medicine Market
8.7.3 SWOT Analysis
8.8 Bio-Rad Laboratories, Inc.
8.8.1 Company Overview
8.8.2 Role of Bio-Rad Laboratories, Inc.in the Global Precision Medicine Market
8.8.3 Key Insights about Financial Health of the Company
8.8.4 SWOT Analysis
8.9 bioMérieux SA.
8.9.1 Company Overview
8.9.2 Role of bioMérieux SA. in the Global Precision Medicine Market
8.9.3 Key Insights about Financial Health of the Company
8.9.4 SWOT Analysis
8.10 Bristol-Myers Squibb Company
8.10.1 Company Overview
8.10.2 Role of Bristol-Myers Squibb Company in the Global Precision Medicine Market
8.10.3 Key Insights about Financial Health of the Company
8.10.4 SWOT Analysis
8.11 Canon Inc.
8.11.1 Company Overview
8.11.2 Role of Canon Inc. in the Global Precision Medicine Market
8.11.3 Key Insights about Financial Health of the Company
8.11.4 SWOT Analysis
8.12 CETICS Healthcare Technologies GmbH
8.12.1 Company Overview
8.12.2 Role CETICS Healthcare Technologies GmbHin the Global Precision Medicine Market
8.12.3 Figure SWOT Analysis
8.13 Danaher Corporation
8.13.1 Company Overview
8.13.2 Role of Danaher Corporation in the Global Precision Medicine Market
8.13.3 Key Insights about Financial Health of the Company
8.13.4 SWOT Analysis
8.14 Eli Lilly and Company Limited
8.14.1 Company Overview
8.14.2 Role of Eli Lilly and Company Limited in the Global Precision Medicine Market
8.14.3 Key Insights about Financial Health of the Company
8.14.4 SWOT Analysis
8.15 Epic Sciences, Inc.
8.15.1 Company Overview
8.15.2 Role Epic Sciences, Inc. in the Global Precision Medicine Market
8.15.3 SWOT Analysis
8.16 F. Hoffmann-La Roche AG
8.16.1 Company Overview
8.16.2 Role of F.Hoffman-LA Roche AG in the Global Precision Medicine Market
8.16.3 Key Insights about Financial Health of the Company
8.16.4 SWOT Analysis
8.17 GE Corporation
8.17.1 Company Overview
8.17.2 Role of GE Corporation in the Global Precision Medicine Market
8.17.3 Key Insights about Financial Health of the Company
8.17.4 SWOT Analysis
8.18 Gilead Sciences, Inc.
8.18.1 Company Overview
8.18.2 Role of Gilead Sciences, Inc. in the Global Precision Medicine Market
8.18.3 Key Insights about Financial Health of the Company
8.18.4 SWOT Analysis
8.19 GlaxoSmithKline Plc
8.19.1 Company Overview
8.19.2 Role of GlaxoSmithKline Plc in the Global Precision Medicine Market
8.19.3 Key Insights about Financial Health of the Company
8.19.4 SWOT Analysis
8.20 IBM Corporation
8.20.1 Company Overview
8.20.2 Role of IBM Corporation in the Global Precision Medicine Market
8.20.3 Key Insights about Financial Health of the Company
8.20.4 SWOT Analysis
8.21 Illumina, Inc.
8.21.1 Company Overview
8.21.2 Role of Illumina, Inc. in the Global Precision Medicine Market
8.21.3 Key Insights about Financial Health of the Company
8.21.4 SWOT Analysis
8.22 Intomics A/S
8.22.1 Company Overview
8.22.2 Role Intomics A/S in the Global Precision Medicine Market
8.22.3 SWOT Analysis
8.23 Johnson & Johnson
8.23.1 Company Overview
8.23.2 Role of Johnson and Johnson in the Global Precision Medicine Market
8.23.3 Key Insights about Financial Health of the Company
8.23.4 SWOT Analysis
8.24 Konica Minolta, Inc.
8.24.1 Company Overview
8.24.2 Role of Konica Minolta, Inc. in the Global Precision Medicine Market
8.24.3 Key Insights about Financial Health of the Company
8.24.4 SWOT Analysis
8.25 Laboratory Corporation of America
8.25.1 Company Overview
8.25.2 Role of Lab Corporation of America in the Global Precision Medicine Market
8.25.3 Key Insights about Financial Health of the Company
8.25.4 SWOT Analysis
8.26 MDxHealth, Inc.
8.26.1 Company Overview
8.26.2 Role of MDx Health, Inc. in the Global Precision Medicine Market
8.26.3 Key Insights about Financial Health of the Company
8.26.4 SWOT Analysis
8.27 Menarini Silicon Biosystems, Inc.
8.27.1 Company Overview
8.27.2 Role Menarini Silicon Biosystems, Inc. in the Global Precision Medicine Market
8.27.3 SWOT Analysis
8.28 Merck & Co., Inc.
8.28.1 Company Overview
8.28.2 Role of Merck & Co., Inc. in the Global Precision Medicine Market
8.28.3 Key Insights about Financial Health of the Company
8.28.4 SWOT Analysis
8.29 Myriad Genetics, Inc.
8.29.1 Company Overview
8.29.2 Role of Myriad Genetics, Inc. in the Global Precision Medicine Market
8.29.3 Key Insights about Financial Health of the Company
8.29.4 SWOT Analysis
8.30 Novartis AG.
8.30.1 Company Overview
8.30.2 Role of Novartis AG in the Global Precision Medicine Market
8.30.3 Key Insights about Financial Health of the Company
8.30.4 SWOT Analysis
8.31 Oracle Corporation.
8.31.1 Company Overview
8.31.2 Role of Oracle Corporation in the Global Precision Medicine Market
8.31.3 Key Insights about Financial Health of the Company
8.31.4 SWOT Analysis
8.32 Pacific Biosciences of California, Inc.
8.32.1 Company Overview
8.32.2 Role of Pacific Biosciences of California, Inc. in the Global Precision Medicine Market
8.32.3 Key Insights about Financial Health of the Company
8.32.4 SWOT Analysis
8.33 Partek, Inc.
8.33.1 Company Overview
8.33.2 Role Partek, Inc. in the Global Precision Medicine Market
8.33.3 SWOT Analysis
8.34 Pfizer, Inc.
8.34.1 Company Overview
8.34.2 Role of Pfizer, Inc. in the Global Precision Medicine Market
8.34.3 Key Insights about Financial Health of the Company
8.34.4 SWOT Analysis
8.35 QIAGEN N.V
8.35.1 Company Overview
8.35.2 Role of QAIGEN N.V in the Global Precision Medicine Market
8.35.3 Key Insights about Financial Health of the Company
8.35.4 SWOT Analysis
8.36 Quest Diagnostics Inc.
8.36.1 Company Overview
8.36.2 Role of Quest Diagnostics Inc. in the Global Precision Medicine Market
8.36.3 Key Insights about Financial Health of the Company
8.36.4 SWOT Analysis
8.37 Randox Laboratories Ltd.
8.37.1 Company Overview
8.37.2 Role of Randox Laboratories Ltd. in the Global Precision Medicine Market
8.37.3 SWOT Analysis
8.38 Sanofi SA
8.38.1 Company Overview
8.38.2 Role of Sanofi SA in the Global Precision Medicine Market
8.38.3 Key Insights about Financial Health of the Company
8.38.4 SWOT Analysis
8.39 Sysmex Corporation
8.39.1 Company Overview
8.39.2 Role of Sysmex Corporation in the Global Precision Medicine Market
8.39.3 Key Insights about Financial Health of the Company
8.39.4 SWOT Analysis
8.40 Teva Pharmaceuticals Industries Ltd.
8.40.1 Company Overview
8.40.2 Role of Teva Pharmaceuticals Industries Ltd. in the Global Precision Medicine Market
8.40.3 Key Insights about Financial Health of the Company
8.40.4 SWOT Analysis
8.41 Thermo Fisher Scientific, Inc.
8.41.1 Company Overview
8.41.2 Role of Thermo Fisher Scientific Inc. in the Global Precision Medicine Market
8.41.3 Key Insights about Financial Health of the Company
8.41.4 SWOT Analysis
8.42 TrovaGene, Inc.
8.42.1 Company Overview
8.42.2 Role of TrovaGene, Inc. in the Global Precision Medicine Market
8.42.3 SWOT Analysis

9 Report Scope and Methodology
9.1 Scope of the Report
9.2 Research Methodology
9.2.1 Primary Research
9.2.2 Secondary Research
9.2.3 Key Data Points from Primary Resources
9.2.4 Key Data Points from Secondary Sources
9.2.5 Data Triangulation

10 List of Annexures
10.1 Recent Key Developments and Strategies
10.2 Product Mapping
10.3 Patent Analysis
10.4 Funding Scenario
10.5 List of Precision Medicine Drugs
10.6 Patent Landscape and Regulatory Bodies
10.7 Cancer Incidence Datasheet
10.8 List of Approved Products
10.9 Competitive Mapping
10.10 PM Initiatives
10.11 List of Universities
10.12 List of Prominent Center of Excellence (CoE)
10.13 Data on Partnerships by Academics, CoE and Industry
10.14 Precision Medicine Drugs Pipeline Analysis

List of Tables
Table 1: Comparison of China and the U.S. Healthcare Statistics
Table 1.1: Initiatives and Programs
Table 2.1: Impact Analysis
Table 2.2: Percentage of Total Regional Aged Population (65 years & above: 2015 & 2030)
Table 2.3: Cancer Incidence by WHO Region, 2012 (Thousands)
Table 2.4: Cancer Incidence Type in Thousand, 2012 (WHO)
Table 2.5: Policy and Guidance Documents from the U.S. FDA
Table 4.1: Pipeline Analysis
Table 4.2: Precision Medicine Drugs Pipeline Analysis
Table 5.1: List of Few FDA Approved Pharmacogenomics Biomarkers in Drug Labelling
Table 5.2: Key Approved Therapeutics with FDA Mandated Companion Diagnostics Tests
Table 5.3: List of FDA Approved Companion Diagnostics
Table 5.4: Commercially Available Primary and Secondary Analysis Tools Providers
Table 6.1: Cancer Precision Medicine Drugs and Indications
Table 6.2: Recent Key Developments
Table 6.3: Infectious Diseases Precision Medicine Drugs and Indications
Table 6.4: Neurology Precision Medicine Drugs and Indications
Table 6.5: Cardiovascular Precision Medicine Drugs/Tests/ and Indications
Table 6.6: Endocrinology Precision Medicine Drugs and Indications
Table 6.7: Gastroenterology Precision Medicine Drugs and Indications
Table 6.8: Precision Drugs for Other Applications
Table 7.1: Funding scenario in Universities

List of Figures
Figure 1: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
Figure 2: Precision Medicine - a Multi-Faceted Approach to Patient Care
Figure 3: Chronic Conditions: Key Statistics: 2017
Figure 4: Long-Term Growth Drivers
Figure 5: Impact Analysis
Figure 6: Global Precision Medicine Market Snapshot
Figure 7: Dominating Segments of Global Precision Medicine Market, 2017 and 2028
Figure 8: Global Precision Medicine Market (by Ecosystem), 2017 and 2028
Figure 9: Global Precision Medicine Market, (by Application), 2017 and 2028
Figure 10: Global Precision Medicine Market (by Region), 2017 and 2028
Figure 11: Notable Areas of Strategic Focus across Influential Countries
Figure 12: Strategies Incorporated to Expand the Global Reach
Figure 13: Precision Medicine Funding for Academic Institutions and Research Organizations
Figure 14: A Persuasive Market Entry Strategy for Diagnostics and Pharma & Biotech Companies to Capitalize on Precision Medicine
Figure 15: Plausible Market Penetration Strategy to Shape the Future of Healthcare
Figure 16: Go To Market Strategy
Figure 17: Value Assessment Frameworks
Figure 18: Product/Service Promotion Strategies
Figure 19: Precision Medicine: A Trigger to Unfold Innovative Business Model
Figure 20: Fixable Gaps in the Field of Precision Medicine
Figure 21: Estimated Ratios of Cost per Quality-Adjusted Life Year (QALY) Gained for Precision or Personalized Medicine Tests
Figure 22: Impact of Precision Medicine on Researchers, Manufacturers, and Consumers
Figure 23: Opportunities and Challenges for Researchers, Providers, and Patients
Figure 1.1: Precision Medicine Approach
Figure 1.2: Evolution of Precision Medicine Technology
Figure 1.3: Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
Figure 1.4: Precision Medicine: Remodeling Framework
Figure 1.5: Precision Medicine: Enabling Technologies
Figure 1.6: Structured Big Data Reporting Benefits
Figure 1.7: Generalized Process for the Microarray
Figure 2.1: Market Dynamics of Global Precision Medicine Market
Figure 2.2: Total Number of Genetic Products in Market
Figure 2.3: Total Number of Genetic Products in Market
Figure 2.4: % of Patients Whose Tumors Were Driven by Certain Genetic Mutations That Could Be Targets for Specific Drugs
Figure 2.5: Gene Therapy Products in Pipeline
Figure 2.6: Sales Forecast for Gene Therapy Products (Yescarta and Kymriah), $ Million
Figure 2.7: Precision Medicine Deals (2010-2017)
Figure 3.1: Competitive Landscape, January 2012-December 2018
Figure 3.2: Share of Key Developments and Strategies (January 2012-December 2018)
Figure 3.3: Joint Ventures, Partnerships, Agreements, and Collaborations Share by Companies (January 2012-December 2018)
Figure 3.4: Product launches, Enhancements, and Upgradation Share by Companies (January 2012-December 2018)
Figure 3.5: Product Approvals Share by Companies (January 2012-December 2018)
Figure 3.6: Merger and Acquisitions Share by Companies (January 2012-December 2018)
Figure 3.7: Business Expansion Share by Companies (January 2012-December 2018)
Figure 3.8: Other Developments Share by Companies (January 2012-December 2018)
Figure 3.9: Market Share Analysis by Applied Sciences, 2017
Figure 3.10: Market Share Analysis by Precision Diagnostics, 2017
Figure 3.11: Market Share Analysis by Precision Therapeutics, 2017
Figure 3.12: Market Share Analysis by Digital Health and IT, 2017
Figure 3.13: Porter's Five Forces Analysis
Figure 3.14: Definition of Suppliers and Buyers in the Precision Medicine Market
Figure 3.15: Bargaining Power of Suppliers: Overall Impact, 2015-2028
Figure 3.16: Bargaining Power of Buyers: Overall Impact, 2015-2028
Figure 3.17: Threat of New Entrant: Overall Impact, 2015-2028
Figure 3.18: Threat of Substitute Products: Overall Impact, 2014-2028
Figure 3.19: Intensity of Competitive Rivalry: Overall Impact, 2015-2028
Figure 3.20: Supply Chain Analysis: Global Precision Medicine Market
Figure 4.1: Patent Analysis
Figure 4.2: Role of FDA in Advancing Precision Medicine
Figure 5.1: Precision Medicine: The Ecosystem
Figure 5.2: Global Precision Medicine Market (by Ecosystem)
Figure 5.3: Global Precision Medicine Market (by Ecosystem), 2017-2028
Figure 5.4: Global Precision Medicine Market (by Applied Sciences)
Figure 5.5: Global Precision Medicine Market (by Applied Sciences), 2017-2028
Figure 5.6: Precision Medicine: Omics Sciences
Figure 5.7: Global Precision Medicine Applied Sciences Market (by Type), 2017-2028
Figure 5.8: Precision Medicine: Genomics
Figure 5.9: Global Precision Medicine Genomics Market, 2017-2028
Figure 5.10: Global Precision Medicine Genomics Market (by Technology), 2017-2028
Figure 5.11: Global Precision Medicine PCR Market, 2017-2028
Figure 5.12: Global Precision Medicine PCR Market (by Product Type), 2017-2028
Figure 5.13: Global Precision Medicine PCR Market (by End User), 2017-2028
Figure 5.14: Global Precision Medicine PCR Market (by Region), 2017-2028
Figure 5.15: Evolution of Next-Generation Sequencing
Figure 5.16: Global Precision Medicine NGS Market, 2017-2028
Figure 5.17: Global Precision Medicine PM NGS Market (by Product Type), 2017-2028
Figure 5.18: Global Precision Medicine NGS Market (by Technology), 2017-2028
Figure 5.19: Global Precision Medicine NGS Market (by End User), 2017-2028
Figure 5.20: Global Precision Medicine NGS Market (by Region), 2017-2028
Figure 5.21: Global Precision Medicine Genome Editing Market, 2017-2028
Figure 5.22: Global Precision Medicine Genome Editing Market (by Product Type), 2017-2028
Figure 5.23: Global Precision Medicine Genome Editing Market (by End User), 2017-2028
Figure 5.24: Global Precision Medicine Genome Editing Market (by Region), 2017-2028
Figure 5.25: Global Precision Medicine Other Technologies Market, 2017-2028
Figure 5.26: Global Precision Medicine Other Technologies Market (by Region), 2017-2028
Figure 5.27: Clinical Applications of Pharmacogenomics Testing
Figure 5.28: Role of Biomarkers in Pharmacogenomics
Figure 5.29: Role of FDA In Pharmacogenomics
Figure 5.30: Global Precision Medicine Pharmacogenomics Market, 2017-2028
Figure 5.31: Global Precision Medicine Pharmacogenomics Market (by Pharmacogenomics Services), 2017-2028
Figure 5.32: Global Precision Medicine Pharmacogenomics Market (by End User), 2017-2028
Figure 5.33: Global Precision Medicine Pharmacogenomics Market (by Region), 2017-2028
Figure 5.34: Global Precision Medicine Other Applied Sciences Market, 2017-2028
Figure 5.35: Precision Medicine: Diagnostics
Figure 5.36: Global Precision Medicine Market (by Precision Diagnostics)
Figure 5.37: Global Precision Medicine Market (by Precision Diagnostics), 2017-2028
Figure 5.38: Global Precision Medicine Diagnostics Market (by Type), 2017-2028
Figure 5.39: General Workflow of a Molecular Diagnostic Assay
Figure 5.40: Global Precision Medicine Diagnostics Market (by Molecular Diagnostics)
Figure 5.41: Global Precision Medicine Molecular Diagnostics Market, 2017-2028
Figure 5.42: Global Precision Medicine Molecular Diagnostics Market (by Type), 2017-2028
Figure 5.43: Benefits and Risks Associated with NIPT
Figure 5.44: Global Precision Medicine NIPT Market, 2017-2028
Figure 5.45: Global Precision Medicine NIPT Market (by Platform), 2017-2028
Figure 5.46: Global Precision Medicine NIPT Market (by Region), 2017-2028
Figure 5.47: Drug and Companion Diagnostics Development Process
Figure 5.48: Benefits and Risks Associated with Companion Diagnostics
Figure 5.49: Global Precision Medicine Companion Diagnostics Market, 2017-2028
Figure 5.50: Global Precision Medicine Companion Diagnostics Market (by Technology), 2017-2028
Figure 5.51: Global Precision Medicine Companion Diagnostics Market (by Indication), 2017-2028
Figure 5.52: Global Precision Medicine Companion Diagnostics Market (by Region), 2017-2028
Figure 5.53: Clinical Applications of Liquid Biopsy
Figure 5.54: Global Precision Medicine Liquid Biopsy Market, 2017-2028
Figure 5.55: Global Precision Medicine Liquid Biopsy Market (by Indication), 2017-2028
Figure 5.56: Global Precision Medicine Liquid Biopsy Market (by Region), 2017-2028
Figure 5.57: Global Precision Medicine Other Molecular Diagnostics Market, 2017-2028
Figure 5.58: Global Precision Medicine Other Molecular Diagnostics Market (by Type), 2017-2028
Figure 5.59: Global Precision Medicine Other Molecular Diagnostics Market (by Region), 2017-2028
Figure 5.60: Global Precision Medicine Medical Imaging Market, 2017-2028
Figure 5.61: Global Precision Medicine Medical Imaging Market (by Type), 2017-2028
Figure 5.62: Global Precision Medicine Medical Imaging Market (by Region), 2017-2028
Figure 5.63: Global Precision Medicine Imaging Analytics Market, 2017-2028
Figure 5.64: Global Precision Medicine CADx Market, 2017-2028
Figure 5.65: Global Precision Medicine Digital Health and Information Technology Market, 2017-2028
Figure 5.66: Global Precision Medicine Digital Health and Information Technology Market (by Type), 2017-2028
Figure 5.67: Global Precision Medicine Digital Health and Information Technology Market (by End User), 2017-2028
Figure 5.68: Global Precision Medicine Digital Health and Information Technology Market (by Region), 2017-2028
Figure 5.69: Global Precision Medicine CDSS Market, 2017-2028
Figure 5.70: Big Data Attributes
Figure 5.71: Global Precision Medicine Big Data Analytics Market, 2017-2028
Figure 5.72: Big Data Analytics: Key Benefits
Figure 5.73: Global Precision Medicine IT Infrastructure Market, 2017-2028
Figure 5.74: Global Precision Medicine IT Infrastructure Market (by Type), 2017-2028
Figure 5.75: Global Precision Medicine Genomics Informatics Market, 2017-2028
Figure 5.76: Global Precision Medicine Genomics Informatics Market (by Product Type), 2017-2028
Figure 5.77: Global Precision Medicine In-Silico Informatics Market, 2017-2028
Figure 5.78: Global Precision Medicine Mobile Health Market, 2017-2028
Figure 5.79: Global Precision Medicine Therapeutics Market, 2017-2028
Figure 5.80: Global Precision Medicine Therapeutics Market (by Type), 2017-2028
Figure 5.81: Global Precision Medicine Clinical Trials Market, 2017-2028
Figure 5.82: Global Precision Medicine Clinical Trials Market (by Region), 2017-2028
Figure 5.83: Types of Cell Therapy
Figure 5.84: Global Precision Medicine Cell Therapy Market, 2017-2028
Figure 5.85: Global Precision Medicine Cell Therapy Market (by Region), 2017-2028
Figure 5.86: Global Precision Medicine Drug Discovery and Research Market, 2017-2028
Figure 5.87: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028
Figure 5.88: Types of Gene Therapy
Figure 5.89: Types of Gene Therapy
Figure 5.90: Global Precision Medicine Gene Therapy Market, 2017-2028
Figure 5.91: Global Precision Medicine Drug Discovery and Research Market (by Region), 2017-2028
Figure 6.1: Therapeutic Areas in Precision Medicine
Figure 6.2: Global Precision Medicine Applications Market, 2017-2028
Figure 6.3: Types of Cancer
Figure 6.4: Global Precision Medicine Oncology Market, 2017-2028
Figure 6.5: Global Precision Medicine Infectious Diseases Market, 2017-2028
Figure 6.6: Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 6.7: Global Precision Medicine Neurology/Physiatry Market, 2017-2028
Figure 6.8: Global Precision Medicine Cardiovascular Market, 2017-2028
Figure 6.9: Global Precision Medicine Lifestyle and Endocrinology Market, 2017-2028
Figure 6.10: Global Precision Medicine Gastroenterology Market, 2017-2028
Figure 6.11: Global Precision Medicine Other Applications Market, 2017-2028
Figure 7.1: Global Precision Medicine Market (by Region)
Figure 7.2: Global Precision Medicine Market (by Region), 2017 and 2028
Figure 7.3: Global Precision Medicine Market (by Region), 2017-2028
Figure 7.4: North America Precision Medicine Market, 2017-2028
Figure 7.5: North America Precision Medicine Market (by Country), 2017-2028
Figure 7.6: North America Precision Medicine Market (by Ecosystem), 2017-2028
Figure 7.7: The U.S. Precision Medicine Market, 2017-2028
Figure 7.8: Canada Precision Medicine Market, 2017-2028
Figure 7.9: Europe Precision Medicine Market, 2017-2028
Figure 7.10: Europe Precision Medicine Market (by Country), 2017-2028
Figure 7.11: Europe Precision Medicine Market (by Ecosystem), 2017-2028
Figure 7.12: Germany Precision Medicine Market, 2017-2028
Figure 7.13: France Precision Medicine Market, 2017-2028
Figure 7.14: Italy Precision Medicine Market, 2017-2028
Figure 7.15: The U.K. Precision Medicine Market, 2017-2028
Figure 7.16: Spain Precision Medicine Market, 2017-2028
Figure 7.17: Rest-of-Europe Precision Medicine Market, 2017-2028
Figure 7.18: Asia-Pacific Precision Medicine Market, 2017-2028
Figure 7.19: Asia-Pacific Precision Medicine Market (by Country), 2017-2028
Figure 7.20: Asia-Pacific Precision Medicine Market (by Ecosystem), 2017-2028
Figure 7.21: China Precision Medicine Market, 2017-2028
Figure 7.22: Japan Precision Medicine Market, 2017-2028
Figure 7.23: Australia Precision Medicine Market, 2017-2028
Figure 7.24: India Precision Medicine Market, 2017-2028
Figure 7.25: Rest-of- Asia-Pacific Precision Medicine Market, 2017-2028
Figure 7.26: Latin America Precision Medicine Market, 2017-2028
Figure 7.27: Latin America Precision Medicine Market (by Country), 2017-2028
Figure 7.28: Latin America Precision Medicine Market (by Ecosystem), 2017-2028
Figure 7.29: Brazil Precision Medicine Market, 2017-2028
Figure 7.30: Mexico Precision Medicine Market, 2017-2028
Figure 7.31: Rest-of-Latin America Precision Medicine Market, 2017-2028
Figure 7.32: Rest-of-the-World Precision Medicine Market, 2017-2028
Figure 7.33: Major Countries in the Middle East Precision Medicine Market
Figure 8.1: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017
Figure 8.2: Abbott Laboratories: Revenue (by Business Segment), 2015-2017
Figure 8.3: Abbott Laboratories: Revenue (by Region), 2015-2017
Figure 8.4: Abbott Laboratories R&D Expenditure, 2015-2017
Figure 8.5: Amgen Inc.: Overall Financials, 2015-2017
Figure 8.6: Amgen Inc.: Revenue (by Region), 2015-2017
Figure 8.7: Amgen Inc. R&D Expenditure, 2014-2017
Figure 8.8: ANGLE plc: Overall Financials, 2015-2017
Figure 8.9: ANGLE plc: Revenue (by Region), 2015-2017
Figure 8.10: ANGLE plc R&D Expenditure, 2014-2017
Figure 8.11: Astellas Pharma Inc.: Overall Financials, 2015-2017
Figure 8.12: Astellas Pharma Inc.: Revenue (by Region), 2015-2017
Figure 8.13: Astellas Pharma Inc. R&D Expenditure, 2015-2017
Figure 8.14: Astra Zeneca PLC : Overall Financials, 2015-2017
Figure 8.15: Astra Zeneca PLC: Revenue (by Business Segment), 2015-2017
Figure 8.16: Astra Zeneca PLC: Revenue (by Region), 2015-2017
Figure 8.17: Astra Zeneca PLC R&D Expenditure, 2014-2017
Figure 8.18: Bio-Rad Laboratories, Inc: Overall Financials, 2015-2017
Figure 8.19: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2015-2017
Figure 8.20: Bio-Rad Laboratories, Inc: Revenue (by Region), 2015-2017
Figure 8.21: Bio-Rad Laboratories, Inc. R&D Expenditure, 2014-2017
Figure 8.22: bioMérieux SA.: Overall Financials, 2015-2017
Figure 8.23: bioMérieux SA.: Revenue (by Business Segment), 2015-2017
Figure 8.24: bioMérieux SA.: Revenue (by Region), 2015-2017
Figure 8.25: bioMérieux SA. R&D Expenditure, 2014-2017
Figure 8.26: Bristol-Myers Squibb Company: Overall Financials, 2015-2017
Figure 8.27: Bristol-Myers Squibb Company: Revenue (by Region), 2015-2017
Figure 8.28: Bristol-Myers Squibb Company R&D Expenditure, 2015-2017
Figure 8.29: Canon Inc.: Overall Financials, 2015-2017
Figure 8.30: Canon Inc.: Revenue (by Segment), 2015-2017
Figure 8.31: Canon Inc.: Revenue (by Region), 2015-2017
Figure 8.32: Canon Inc.: R&D Expenditure, 2015-2017
Figure 8.33: Danaher Corporation: Overall Financials, 2015-2017
Figure 8.34: Danaher Corporation: Revenue (by Business Segment), 2015-2017
Figure 8.35: Danaher Corporation: Revenue (by Region), 2015-2017
Figure 8.36: Danaher Corporation R&D Expenditure, 2014-2017
Figure 8.37: Eli Lilly and Company Limited: Overall Financials, 2015-2017
Figure 8.38: Eli Lilly and Company Limited: Revenue (by Business Segment), 2015-2017
Figure 8.39: Eli Lilly and Company Limited: Revenue (by Region), 2015-2017
Figure 8.40: Eli Lilly and Company Limited R&D Expenditure, 2014-2017
Figure 8.41: F.Hoffman-LA Roche AG: Overall Financials, 2015-2017
Figure 8.42: F.Hoffman-LA Roche AG: Revenue (by Business Segment), 2015-2017
Figure 8.43: F.Hoffman-LA Roche AG : Revenue (by Region), 2015-2017
Figure 8.44: F.Hoffman-LA Roche AG R&D Expenditure, 2014-2017
Figure 8.45: GE Corporation Limited: Overall Financials, 2015-2017
Figure 8.46: GE Corporation: Revenue (by Business Segment), 2015-2017
Figure 8.47: GE Corporation: Revenue (by Region), 2015-2017
Figure 8.48: GE Corporation R&D Expenditure, 2014-2017
Figure 8.49: Gilead Sciences, Inc.: Overall Financials, 2015-2017
Figure 8.50: Gilead Sciences, Inc.: Revenue (by Business Segment), 2015-2017
Figure 8.51: Gilead Sciences, Inc.: Revenue (by Region), 2015-2017
Figure 8.52: Gilead Sciences, Inc. R&D Expenditure, 2014-2017
Figure 8.53: GlaxoSmithKline Plc: Overall Financials, 2015-2017
Figure 8.54: GlaxoSmithKline Plc: Revenue (by Business Segment), 2015-2017
Figure 8.55: GlaxoSmithKline Plc: Revenue (by Region), 2015-2017
Figure 8.56: GlaxoSmithKline Plc R&D Expenditure, 2014-2017
Figure 8.57: IBM Corporation: Overall Financials, 2015-2017
Figure 8.58: IBM Corporation: Revenue (by Business Segment), 2015-2017
Figure 8.59: IBM Corporation: Revenue (by Region), 2015-2017
Figure 8.60: IBM Corporation R&D Expenditure, 2014-2017
Figure 8.61: Illumina, Inc.: Overall Financials, 2015-2017
Figure 8.62: Illumina, Inc.: Revenue (by Business Segment), 2015-2017
Figure 8.63: Illumina, Inc.: Revenue (by Region), 2015-2017
Figure 8.64: Illumina, Inc. R&D Expenditure, 2014-2017
Figure 8.65: Johnson and Johnson: Overall Financials, 2015-2017
Figure 8.66: Johnson and Johnson: Revenue (by Business Segment), 2015-2017
Figure 8.67: Johnson and Johnson Revenue (by Region), 2015-2017
Figure 8.68: Johnson and Johnson R&D Expenditure, 2014-2017
Figure 8.69: Konica Minolta, Inc.: Overall Financials, 2015-2017
Figure 8.70: Konica Minolta, Inc.: Revenue (by Segment), 2015-2017
Figure 8.71: Konica Minolta, Inc.: Revenue (by Region), 2015-2017
Figure 8.72: Konica Minolta, Inc.: R&D Expenditure, 2015-2017
Figure 8.73: Lab Corporation of America: Overall Financials, 2015-2017
Figure 8.74: Lab Corporation of America: Revenue (by Business Segment), 2015-2017
Figure 8.75: Lab Corporation of America: Revenue (by Region), 2015-2017
Figure 8.76: MDx Health, Inc.: Overall Financials, 2015-2017
Figure 8.77: MDx Health, Inc. R&D Expenditure, 2014-2017
Figure 8.78: Merck & Co., Inc.: Overall Financials, 2015-2017
Figure 8.79: Merck & Co., Inc.: Revenue (by Business Segment), 2015-2017
Figure 8.80: Merck & Co., Inc.: Revenue (by Region), 2015-2017
Figure 8.81: Merck & Co., Inc. R&D Expenditure, 2015-2017
Figure 8.82: Myriad Genetics, Inc.: Overall Financials, 2015-2017
Figure 8.83: Myriad Genetics, Inc.: Revenue (by Business Segment), 2015-2017
Figure 8.84: Myriad Genetics, Inc.: Revenue (by Region), 2015-2017
Figure 8.85: Myriad Genetics, Inc. R&D Expenditure, 2015-2017
Figure 8.86: Novartis AG: Overall Financials, 2015-2017
Figure 8.87: Novartis AG: Revenue (by Business Segment), 2015-2017
Figure 8.88: Novartis AG: Revenue (by Region), 2015-2017
Figure 8.89: Novartis AG R&D Expenditure, 2015-2017
Figure 8.90: Oracle Corporation: Overall Financials, 2015-2017
Figure 8.91: Oracle Corporation: Revenue (by Region), 2015-2017
Figure 8.92 Oracle Corporation R&D Expenditure, 2015-2017
Figure 8.93: Pacific Biosciences of California, Inc.: Overall Financials, 2015-2017
Figure 8.94: Pacific Biosciences of California, Inc.: Revenue (by Region), 2015-2017
Figure 8.95: Pacific Biosciences of California, Inc. R&D Expenditure, 2015-2017
Figure 8.96: Pfizer, Inc.: Overall Financials, 2015-2017
Figure 8.97: Pfizer, Inc.: Revenue (by Business Segment), 2015-2017
Figure 8.98: Pfizer, Inc.: Revenue (by Region), 2015-2017
Figure 8.99: Pfizer, Inc. R&D Expenditure, 2015-2017
Figure 8.100: QIAGEN N.V: Overall Financials, 2015-2017
Figure 8.101: QIAGEN N.V: Revenue (by Business Segment), 2015-2017
Figure 8.102: QIAGEN N.V: Revenue (by Region), 2015-2017
Figure 8.103: QIAGEN N.V R&D Expenditure, 2015-2017
Figure 8.104: Quest Diagnostics Inc.: Overall Financials, 2015-2017
Figure 8.105: Quest Diagnostics Inc.: Revenue (by Business Segment), 2015-2017
Figure 8.106: Quest Diagnostics Inc.: Revenue (by Region), 2015-2017
Figure 8.107: Sanofi SA: Overall Financials, 2015-2017
Figure 8.108: Sanofi SA: Revenue (by Business Segment), 2015-2017
Figure 8.109: Sanofi SA: Revenue (by Region), 2015-2017
Figure 8.110 Sanofi SA R&D Expenditure, 2015-2017
Figure 8.111: Sysmex Corporation: Overall Financials, 2015-2017
Figure 8.112: Sysmex Corporation: Revenue (by Business Segment), 2015-2017
Figure 8.113: Sysmex Corporation R&D Expenditure, 2015-2017
Figure 8.114: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2015-2017
Figure 8.115: Teva Pharmaceuticals Industries Ltd.: Revenue (by Business Segment), 2015-2017
Figure 8.116: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2015-2017
Figure 8.117: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2015-2017
Figure 8.118: Thermo Fisher Scientific Inc.: Overall Financials, 2015-2017
Figure 8.119: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2015-2017
Figure 8.120: Thermo Fisher Scientific Inc.: Revenue (by Region), 2015-2017
Figure 8.121 Thermo Fisher Scientific Inc. R&D Expenditure, 2015-2017
Figure 8.122: TrovaGene,Inc.: Overall Financials, 2015-2017
Figure 9.1: Global Precision Medicine Market Segmentation
Figure 9.2: Figure Scope
Figure 9.3: Key data points from primary resources
Figure 9.4: Key data points from secondary resources
Figure 9.5: Top-down Approach (Segment-wise Analysis)
Figure 9.6: Bottom-Up Approach (Segmental Analysis)
Figure 9.7: Research Methodology Snapshot
Figure 9.8: Assumptions and Limitations
Figure 9.9: Considered Factors for Data Prediction and Modelling

Note: Product cover images may vary from those shown
3 of 7

Loading
LOADING...

4 of 7

FEATURED COMPANIES

  • Abbott Laboratories
  • Astra Zeneca PLC
  • Epic Sciences, Inc.
  • IBM Corporation
  • MDxHealth, Inc.
  • Partek, Inc.
  • MORE

There has been a continuous search in the medical world for better treatment and prevention approaches for various infectious and non-infectious diseases, paving the  way for the most awaited changes in personalized medicines. In recent years, the impressive research on biologics for the development of DNA, the study of the human genome, and the development of precision diagnostic tools and software has opened new hopes to develop promising precision medicine for different types of cancers, infectious diseases, and rare and orphan diseases. Advancements in genome analysis, especially in the development of vaccine platforms and accelerating adoption of companion diagnostics in routine healthcare procedures, coupled with ongoing clinical trials, have resulted in the evolution of precision medicine – a healthcare model (comprising treatment, practices, and healthcare products like medicine) that is customized as per the patient.

Precision medicine has significantly positioned itself as the hotspot of mainstream medicine. With aggressive technological developments, such as next-generation sequencing and fierce competition in the field of targeted molecular therapy, precision medicine portrays itself as a sophisticated medical care model  while simultaneously opening avenues for public health care. However, despite its proven potential, the technology is still in its infancy and needs to evolve  while overcoming many deficiencies and challenges.

On the other hand, immense expectations are associated with precision medicine in terms of its capability to define Diseases, based on molecular characteristics and environmental susceptibility factors. The fulfilment of those expectations need pre-requisites such as the construction of a novel data network, integration of clinical data from patients, and further expansion of research aimed at finding the molecular makeup of diseases. Also, multi-omics analysis and cross-industry collaborations will be instrumental at realizing the benefits of precision medicine with its fullest potential. To, bolster precision medicine, genomic sequencing is of utmost importance, and since 2003 (after the completion of Human Genome Project), genomic sequencing has attained great strides in terms of both cost and time. This genome sequencing technology is so advanced now that a single genome can be sequenced under $1000 within a day. The cost has plummeted to approximately three million times and the time taken for the process has reduced 3,000 times since the first genome was ever sequenced.

The purpose of the study on global precision medicine market is to gain a holistic view of the precision medicine market in terms of various influencing factors, such as the trends, regulatory frameworks, and technological advancements. The report constitutes a detailed study of the different kinds of products and technologies associated with the global precision medicine market. The market has been segmented into “ecosystem”, “application type”, and “region”. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in the reader form well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

The global precision medicine market is anticipated to reach $216.75 billion by 2028, witnessing a CAGR of 10.64% in the forecast period 2018-2028. Some of the factors such as the emergence of liquid biopsy, increasing demand for multiplex assays to target emerging diseases, reduced adverse drug reactions through pharmacogenomics testing, and increasing focus on target-based therapies are acting as significant factors propelling the growth of the global precision medicine market.

In terms of ecosystem, the global precision medicine market is dominated by applied sciences. This dominance can be attributed to the ongoing advancements in the field of human genomics and innovation of new healthcare technologies such as next-generation sequencing, high throughput screening (HTS), and digital polymerase chain reaction (PCR). The completion of the first human genome project in the 1990s has created the platform for the development of further enhanced pharmacogenomics solutions in applied sciences. At present, government initiatives are focused on launching a large number of genomic tests and drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology and cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.

In terms of application type, the global precision medicine market is dominated by oncology. In 2017, the market for oncology was valued $38.01 billion. Cancer is classified to be a disease of genetic mutation, as a result of genetic changes. Technological advancement has generated a better understanding of tumor and led to more effective treatment strategies that are personalized to the genetic profile of patients suffering from different types of cancer.

In terms of regional potential, North America is the leading contributor to the global precision medicine market and contributed approximately 47% of the global market values in 2017. This can be attributed to increasing usage of genomics and pharmacogenomics in the development of personalized medicines, and high income of patients to afford costly diagnostic and genetic tests.  Also, in the year 2015, the launch of Precision Medicine Initiative (PMI) by the then U.S. president, Barack Obama, completely revolutionized the process of healthcare delivery in the nation. The initiative was aimed at irradiating the already existing “one-size-fits-all” approach of treatment and hence improve patient outcomes while minimalizing healthcare costs. In financial terms, the initiative was worth $215 million and significantly accelerated the discovery of biomedical tools, knowledge, and therapies to assist clinicians to come up with the treatment that best serves the individual need of the patients.

The key players who have been contributing significantly to the global precision medicine market are Pfizer, Inc., Merck & Co., Inc., Abbott Laboratories, GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Almac Group Ltd., Bio-Rad Laboratories, Inc. Johnson and Johnson, and bioMérieux S.A., among others.

Note: Product cover images may vary from those shown
5 of 7
  • Abbott Laboratories
  • Almac Group Ltd.
  • Amgen Inc.
  • ANGLE plc
  • Astellas Pharma Inc.
  • Astra Zeneca PLC
  • ASURAGEN INC.
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA.
  • Bristol-Myers Squibb Company
  • Canon Inc.
  • CETICS Healthcare Technologies GmbH
  • Danaher Corporation
  • Eli Lilly and Company Limited
  • Epic Sciences, Inc.
  • F. Hoffmann-La Roche AG
  • GE Corporation
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • IBM Corporation
  • Illumina, Inc.
  • Intomics A/S
  • Johnson & Johnson
  • Konica Minolta, Inc.
  • Laboratory Corporation of America
  • MDxHealth, Inc.
  • Menarini Silicon Biosystems, Inc.
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Oracle Corporation
  • Pacific Biosciences of California, Inc.
  • Partek, Inc.
  • Pfizer, Inc.
  • QIAGEN N.V
  • Quest Diagnostics Inc.
  • Randox Laboratories Ltd.
  • Sanofi SA
  • Sysmex Corporation
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific, Inc.
  • TrovaGene, Inc.
Note: Product cover images may vary from those shown
6 of 7

Loading
LOADING...

7 of 7
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4748231
Adroll
adroll